Methanolic Extract of
Humans
Apoptosis
/ drug effects
Cell Line, Tumor
Plant Extracts
/ pharmacology
G1 Phase Cell Cycle Checkpoints
/ drug effects
Cimicifuga
/ chemistry
Brain Neoplasms
/ drug therapy
Glioma
/ drug therapy
Methanol
/ chemistry
Glioblastoma
/ drug therapy
Cell Survival
/ drug effects
Cell Movement
/ drug effects
Epithelial-Mesenchymal Transition
/ drug effects
Temozolomide
/ pharmacology
Autophagy
/ drug effects
Antineoplastic Agents, Phytogenic
/ pharmacology
Neoplasm Metastasis
Cell Proliferation
/ drug effects
Cimicifuga foetida
apoptosis
cell cycle arrest
glioma
metastasis inhibition
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
24
08
2024
revised:
20
09
2024
accepted:
24
09
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is among the most aggressive and challenging brain tumors, with limited treatment options. The effects of CF-ME and its index compounds (caffeic acid, cimifugin, ferulic acid, and isoferulic acid) on GBM cell viability were assessed using MTT assays on U87 MG, A172, and T98G cell lines. The ability of CF-ME to induce cell cycle arrest, apoptosis, and autophagy and inhibit metastasis was evaluated using flow cytometry, Western blotting, and functional assays. Additionally, the synergistic potential of CF-ME with temozolomide (TMZ) was explored. CF-ME significantly reduced GBM cell viability in a dose- and time-dependent manner, induced G1 phase cell cycle arrest, promoted apoptosis via caspase activation, and triggered autophagy. CF-ME also inhibited GBM cell invasion, migration, and adhesion, likely by modulating epithelial-mesenchymal transition (EMT) markers. Combined with TMZ, CF-ME further enhanced reduced GBM cell viability, suggesting a potential synergistic effect. However, the individual index compounds of CF-ME exhibited only modest inhibitory effects, indicating that the full anti-glioma activity may result from the synergistic interactions among its components. CF-ME exhibited potent anti-glioma activity through multiple mechanisms, including cell cycle arrest, apoptosis, autophagy, and the inhibition of metastasis. Combining CF-ME with TMZ further enhanced its therapeutic potential, making it a promising candidate for adjuvant therapy in glioblastoma treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma multiforme (GBM) is among the most aggressive and challenging brain tumors, with limited treatment options.
METHODS
METHODS
The effects of CF-ME and its index compounds (caffeic acid, cimifugin, ferulic acid, and isoferulic acid) on GBM cell viability were assessed using MTT assays on U87 MG, A172, and T98G cell lines. The ability of CF-ME to induce cell cycle arrest, apoptosis, and autophagy and inhibit metastasis was evaluated using flow cytometry, Western blotting, and functional assays. Additionally, the synergistic potential of CF-ME with temozolomide (TMZ) was explored.
RESULTS
RESULTS
CF-ME significantly reduced GBM cell viability in a dose- and time-dependent manner, induced G1 phase cell cycle arrest, promoted apoptosis via caspase activation, and triggered autophagy. CF-ME also inhibited GBM cell invasion, migration, and adhesion, likely by modulating epithelial-mesenchymal transition (EMT) markers. Combined with TMZ, CF-ME further enhanced reduced GBM cell viability, suggesting a potential synergistic effect. However, the individual index compounds of CF-ME exhibited only modest inhibitory effects, indicating that the full anti-glioma activity may result from the synergistic interactions among its components.
CONCLUSIONS
CONCLUSIONS
CF-ME exhibited potent anti-glioma activity through multiple mechanisms, including cell cycle arrest, apoptosis, autophagy, and the inhibition of metastasis. Combining CF-ME with TMZ further enhanced its therapeutic potential, making it a promising candidate for adjuvant therapy in glioblastoma treatment.
Identifiants
pubmed: 39408228
pii: nu16193254
doi: 10.3390/nu16193254
pii:
doi:
Substances chimiques
Plant Extracts
0
Methanol
Y4S76JWI15
Temozolomide
YF1K15M17Y
Antineoplastic Agents, Phytogenic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Kaohsiung Medical University Research Foundation
ID : KMU-Q108022
Organisme : Kaohsiung Medical University Research Foundation
ID : KMU-M109019
Organisme : Kaohsiung Medical University Research Foundation
ID : KMU-M111008
Organisme : Kaohsiung Medical University Research Foundation
ID : KMU-M112028
Organisme : National Science and Technology Council
ID : MOST109-2320-B-037-020